SCHEMBL13766904

SCHEMBL13766904

CC(C)COc1c(C(=O)NC2C3CC4CC(C3)CC2C4)cnn1CCN

nearest known ligand 0.47

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 16/20 0.47
LMNA P02545 2/20 0.43
HTT P42858 1/20 0.43
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13766835 0.91 HSD11B1 (0.48) HSD11B1LMNAHTTHPGDSMN1; SMN2
SCHEMBL13767087 0.89 HSD11B1 (0.47) HSD11B1LMNAHTT
SCHEMBL13766905 0.87 HSD11B1 (0.43) HSD11B1LMNAHTTHPGDSMN1; SMN2
SCHEMBL13766843 0.87 HSD11B1 (0.40) HSD11B1LMNAHTT
SCHEMBL13767049 0.87 HSD11B1 (0.46) HSD11B1LMNAHTT
SCHEMBL13766851 0.86 HSD11B1 (0.44) HSD11B1LMNAHTT
SCHEMBL13766961 0.86 HSD11B1 (0.56) HSD11B1LMNAHTTHPGDSMN1; SMN2
SCHEMBL13767223 0.86 HSD11B1 (0.40) HSD11B1LMNAHTT
SCHEMBL13766834 0.86 HSD11B1 (0.47) HSD11B1LMNAHTT
SCHEMBL13766842 0.85 HSD11B1 (0.43) HSD11B1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324265-B2 Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-12-04 US disclosed
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2009-07-02 US disclosed
EP-1953145-A1 HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON 11- -HYDROXYSTEROID DEHYDROGENASE TYPE I Shionogi & Co., Ltd. (JP) 2008-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY HSD17B1, HSD11B1, HSD3B1 HSD11B1 2/4885LMNA 2271/4885HTT 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.